ObjectiveTo investigate the effect of volume embolization ratio(VER) in evaluating the embolization efficacy of aneurysms.MethodsFifty-three patients who received intracranial aneurysm embolization surgery were all treated with detachable coils endovascular embolization,While fifty-seven intracranial aneurysms were treated.The VER was calculated and the relationships between the VER values and the size,the neck,embolization degree of intracranial aneurysm were analyzed.ResultsThe VER of small,medium,large,and giant aneurysms were (40.8 ± 26.5 )％,( 18.6 ± 16.1 )％,(2.3 ± 2.1 )％,(0.4 ±0.1 )％,respectively,which had statistical significance (F =7.091,P ＜ 0.01 ).The VER of wide-necked and narrow-necked aneurysms were (27.5 ± 23.1 )％,(29.4 ± 26.6)％,which had no statistical significance(P ＞0.05 ).The VER of complete embolization,neck residual and partial embolization were (41.8 ± 29.3 )％,(31.4 ± 21.2)％,( 12.3 ± 15.1 )％,respectively,which had statistical differences (F =7.970,P ＜ 0.01 ).ConclusionsThe VER is an objective index to evaluate the embolization degree of aneurysms.It has certain prediction significance for the efficacy judgement of embolization of aneurysms.

Obj ective To observe the clinical effect of edaravone on treatment of patients with acute cerebral infarction (ACI)and its influence on serum superoxide dismutase (SOD)and malondialdehyde (MDA).Methods A total of 64 ACI patients were randomly divided into control group (31 cases)treated with basic medicines and treatment group (33 cases)added with with edar-avone.Clinical efficacy,neurological function deficit improvement rate,American National Insti-tutes of Health Stroke Scale (NIHSS)and Barthel index (BI)as well as serum SOD and MDA level changes in both groups were observed.Results 14 d after treatment,the clinical efficacy in treat-ment group was 84.85%,significantly higher than the 61.29% in control group (P<0.01). NIHSS and Barthel scores were better after treatment than those before (P<0.01),and differences between two groups were also significant (P<0 .05 ).After treatment,SOD level was higher in treatment group (P<0 .0 1 )and lower in control group than those before treatment (P<0 .0 1 ), whereas MDA level was lower in treatment group (P<0 .0 1 )and higher in control group than those before treatment (P<0 .05 ).Additionally,there had no severe adverse responses in both groups. Conclusion On the basis of basic treatment,the application of edaravone has favorable clinical effi-cacy and safety in the treatment of ACI .

Obj ective To observe the clinical effect of edaravone on treatment of patients with acute cerebral infarction (ACI)and its influence on serum superoxide dismutase (SOD)and malondialdehyde (MDA).Methods A total of 64 ACI patients were randomly divided into control group (31 cases)treated with basic medicines and treatment group (33 cases)added with with edar-avone.Clinical efficacy,neurological function deficit improvement rate,American National Insti-tutes of Health Stroke Scale (NIHSS)and Barthel index (BI)as well as serum SOD and MDA level changes in both groups were observed.Results 14 d after treatment,the clinical efficacy in treat-ment group was 84.85%,significantly higher than the 61.29% in control group (P<0.01). NIHSS and Barthel scores were better after treatment than those before (P<0.01),and differences between two groups were also significant (P<0 .05 ).After treatment,SOD level was higher in treatment group (P<0 .0 1 )and lower in control group than those before treatment (P<0 .0 1 ), whereas MDA level was lower in treatment group (P<0 .0 1 )and higher in control group than those before treatment (P<0 .05 ).Additionally,there had no severe adverse responses in both groups. Conclusion On the basis of basic treatment,the application of edaravone has favorable clinical effi-cacy and safety in the treatment of ACI .

BACKGROUND: Osteoporosis (OP) has become a major public health issue, threatening the bone health of middle-aged and elderly people from all around the world. Changes in the gut microbiota (GM) are correlated with the maintenance of bone mass and bone quality. However, research results in this field remain highly controversial, and no systematic review or meta-analysis of the relationship between GM and OP has been conducted. This paper addresses this shortcoming, focusing on the difference in the GM abundance between OP patients and healthy controls based on previous 16S ribosomal RNA (rRNA) gene sequencing results, in order to provide new clinical reference information for future customized prevention and treatment options of OP. METHODS: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), we comprehensively searched the databases of PubMed, Web of Science, Embase, Cochrane Library, and China National Knowledge Infrastructure (CNKI). In addition, we applied the R programming language version 4.0.3 and Stata 15.1 software for data analysis. We also implemented the Newcastle-Ottawa Scale (NOS), funnel plot analysis, sensitivity analysis, Egger's test, and Begg's test to assess the risk of bias. RESULTS: This research ultimately considered 12 studies, which included the fecal GM data of 2033 people (604 with OP and 1429 healthy controls). In the included research papers, it was observed that the relative abundance of Lactobacillus and Ruminococcus increased in the OP group, while the relative abundance for Bacteroides of Bacteroidetes increased (except for Ireland). Meanwhile, Firmicutes, Blautia, Alistipes, Megamonas, and Anaerostipes showed reduced relative abundance in Chinese studies. In the linear discriminant analysis Effect Size (LEfSe) analysis, certain bacteria showed statistically significant results consistently across different studies. CONCLUSIONS: This observational meta-analysis revealed that changes in the GM were correlated with OP, and variations in some advantageous GM might involve regional differences.
Middle Aged ; Aged ; Humans ; Gastrointestinal Microbiome/genetics* ; RNA, Ribosomal, 16S/genetics* ; Genes, rRNA ; Osteoporosis ; Feces